Siegfried Holding Ag · SIX:SFZN
Siegfried — Merger or Acquisition (January 2026)
9 slides from Siegfried's merger presentation, Jan 27, 2026
Slide 1: Siegfried to acquire high-quality small molecules drug substance capacity in the US
Siegfried to acquire high- quality small molecules drug substance capacity in the US Zofingen, January 2026
Slide 2: Disclaimer
Disclaimer This presentation may contain confidential and proprietary information. Any use of the presentation or the information therein without specific permission of Siegfried is prohibited. No representations or warranties of any kind are made with regard to the accuracy or completeness of the i
Slide 3: Siegfried to acquire high-quality small molecules drug substance capacity in the US
Siegfried to acquire high-quality small molecules drug substance capacity in the US Another Siegfried deal: Compelling manufacturing capacity at an attractive price − Siegfried signed binding agreements to acquire small molecules drug substances sites in the US and Australia − Transaction adds highl
Slide 4: Structurally high demand meets limited US capacities
Structurally high demand meets limited US capacities Significant demand from small and large pharma companies for manufacturing capacity for innovative products + Demand push Constrained supply EVOLVE – Re-shoring and supply chain – Less than 15 large-scale resilience initiatives Structural bottlene
Slide 5: Acquired business includes three high-quality drug substances sites
Acquired business includes three high-quality drug substances sites A perfect fit into our existing global network Noramco – Wilmington, DE (US) Purisys – Athens, GA (US) Extractas Bioscience – Tasmania, (AU) – Focused on three product families – CDMO facility for product development, clinical – Lea
Slide 6: Acquisition significantly strengthens our footprint in the US
Acquisition significantly strengthens our footprint in the US Exceptional US-based capacity further enhances our customer offering Comprehensive drug substances offering US footprint passes critical size: 5 sites and 700 employees Wilmington and Pennsville – Complementary pharma manufacturing cluste
Slide 7: Attractive valuation, well below recent expectations for US assets
Attractive valuation, well below recent expectations for US assets Continuation of our highly selective, disciplined and value-accretive M&A Valuation (EV/EBITDA) Transaction 7 8 9 10 11 12 13 14 15 16 17 18 19 20 – Valuation of acquired business is below 10 times Enterprise Value / EBITDA, below ou
Slide 8: A decisive step in the execution of our strategy EVOLVE+
A decisive step in the execution of our strategy EVOLVE+ Transaction further accelerates profitable growth EVOLVE+ Broaden our Grow existing core Enter and grow new areas technological offering Small molecules (DS and DP) DS antibodies Advanced production technologies End-to-end offering of DS and D
Slide 9: Thank you for your attention
Siegfried | Thank you for your attention